Preclinical News and Research

RSS

Antibodies targeting GPNMB may slow Parkinson's disease progression

Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson's disease (PD).

12 May 2026

Implantable cytokine factories show promise against advanced ovarian cancer

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality.

12 May 2026

Cannabis compounds may improve metabolism and reduce diabetes risk

A University of California, Riverside preclinical study is shedding light on a long-observed but poorly understood phenomenon: chronic cannabis users tend to have lower body weight and a reduced risk of developing type 2 diabetes, despite the drug's well-known tendency to increase appetite.

11 May 2026

A century of safety: Aluminium vaccine adjuvants do not raise serious long-term health risks

A BMJ systematic review of 59 human studies found no evidence supporting causal links between aluminum-adjuvanted vaccines and serious or long-term outcomes such as autism spectrum disorder, asthma, autoimmune conditions, or other chronic illnesses. The most consistent adverse events were uncommon, local, self-limited persistent nodules or granulomas, likely reflecting delayed-type hypersensitivity.

11 May 2026

New study reveals how slow-growing cells drive breast cancer relapse

A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment.

11 May 2026

Copper-based nanoplatform shows promise against metastatic tumor growth

What happens if cancer cells lose both their mitochondrial energy supply and their glycolytic backup system? This question is central to a new study published in Research by researchers from Northwestern Polytechnical University and collaborating institutions.

10 May 2026

Advanced 3D heart models could transform cardiovascular drug discovery

Cardiovascular disease remains a leading global health burden, yet many preclinical systems still struggle to predict how candidate drugs will perform in the human heart.

10 May 2026

Could a fingerprick at home flag your Alzheimer's risk? New study says yes

Researchers demonstrated that self-administered fingerprick blood tests measuring p-tau217 and GFAP, returned by post, correlate strongly with venous blood biomarkers and cognitive performance across the Alzheimer's disease continuum. Combined with computerized cognitive testing, this at-home approach offers a scalable, patient-friendly tool for triaging individuals at risk of AD-related impairment.

10 May 2026

Study challenges assumptions about testosterone’s role in brain cancer

Scientists have long suspected that androgens, male sex hormones like testosterone, may help tumors grow because the hormones can suppress immune responses to some cancers.

8 May 2026

The power of organoids in speeding up lifesaving drug development

Organoids are miniature tissue or organ models formed by stem cells (including pluripotent stem cells, tissue-specific adult stem cells, etc.) or progenitor cells in an in vitro three-dimensional culture system, which possess structural features and partial functions analogous to their corresponding in vivo organs. In 2009, the Hans Clevers laboratory developed the first intestinal organoid, marking the inception of organoid-based disease modeling.

8 May 2026

Eating eggs regularly reduces Alzheimer’s disease risk

Findings suggest that egg consumption is associated with lower Alzheimer's disease risk, supporting the need for further research on diet and brain health.

8 May 2026

Study reveals how magnetic stimulation repairs depression-related brain circuits

Transcranial magnetic stimulation (TMS) is a non-invasive, FDA-approved therapy that uses brief magnetic pulses to treat depression, particularly in patients who do not respond to medication.

7 May 2026

Scientists identify powerful human antibodies capable of neutralizing measles virus

Scientists at La Jolla Institute for Immunology (LJI) are the first in the world to characterize human antibodies capable of neutralizing measles virus.

7 May 2026

Methylmercury may harm metabolism beyond its known neurological effects

Methylmercury can accumulate in water environments and enter the food chain. Human exposure is of particular concern in communities affected by contaminated rivers, industrial pollution, artisanal gold mining and environmental disasters.

7 May 2026

A new combined therapy to boost the immune system against cancer

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it is properly activated. In many patients, however, this response is too weak or too slow to be effective.

7 May 2026

New immunotherapy strategy overcomes resistance in colorectal cancer treatment

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.

6 May 2026

Testosterone may help limit brain tumor growth in men

In a new National Institutes of Health (NIH)-funded study, scientists at Cleveland Clinic discovered that hormones associated with male development may play a key role in limiting the growth of brain tumors in men.

6 May 2026

Human telomerase shows limited function across different animal species

A new research paper was published in Volume 18 of Aging-US on April 13, 2026, titled "Cross species activity of TERT human telomerase component."

5 May 2026

YAP1 expression drives chemotherapy resistance in small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the YAP1 protein only after treatment with chemotherapy, allowing them to survive by becoming more invasive and leading to treatment resistance with eventual relapse in patients with small cell lung cancer (SCLC).

5 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026